AlenCiken

Positive Topline Results from ENHANCE for Seladelpar

NASDAQ:CBAY   CymaBay Therapeutics Inc
CymaBay Announces Positive Topline Results from ENHANCE for Seladelpar in Patients with Primary Biliary Cholangitis

-The study demonstrated seladelpar to be efficacious, safe and well-tolerated
78.2% of patients on seladelpar 10 mg versus 12.5% on placebo achieved the primary composite outcome after only 3 months (p<0.0001)

-27.3% of patients on seladelpar 10 mg versus zero on placebo normalized ALP by 3 months (p<0.0001)

-Statistically significant improvement in pruritus (p<0. 05 ) for patients with moderate-to-severe itch demonstrated for seladelpar 10 mg versus placebo

-Strongly supports re-initiation of Phase 3 study to confirm the potential of seladelpar to be a best-in-class treatment for PBC

CymaBay Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020

https://finance.yahoo.com/news/cymabay-a...